Quantcast

GE Healthcare Adopts Mirada Medical Atlas-based Contouring for Advanced RT Planning Software

September 19, 2013

GE will license Mirada’s powerful automatic atlas-based contouring software.

Oxford, UK/Denver, CO (PRWEB) September 19, 2013

Mirada Medical, a leading innovator in medical image analysis, announced they have formalized an agreement with General Electric Healthcare, Milwaukee, WI, whereby GE will license Mirada’s powerful automatic atlas-based contouring software for implementation on their AdvantageSim MD 9 virtual simulation software suite for advanced radiation therapy planning. The technology is based on Mirada Medical’s deformable registration software, which is widely regarded as best in class when aligning image data for RT planning.

“In the era of advanced radiation therapy, contouring organs at risk and targets requires an environment and tools that facilitate productivity and accuracy through efficient automated and manual tools and intuitive user interface,” explained András Szentmiklóssy, Global Product Manager, Oncology at GE Healthcare. “Our goal is to harness the potential productivity improvements and registration accuracy provided by the Mirada Medical atlas-based contouring engine to enhance the benefits of AdvantageSim MD 9 to customers,” Szentmiklóssy concluded.

Mirada Medical has been recognized for its leadership in the development of image fusion and deformable registration for more than a decade. The company’s algorithms are modality specific and yield fast, highly accurate results that are the foundation to their suite of high-level RT analysis and planning software tools. Mirada’s zero-click auto contouring uses an atlas, atlases or previously contoured case to improve both productivity and accuracy.

“It takes only seconds to get an initial set of contours when using an atlas or previously contoured case for greater efficiency compared to manual contouring. These can be checked and quickly refined prior to exporting to the treatment planning system," stated Timor Kadir, Chief Science and Technology Officer for Mirada Medical. “Another benefit of auto contouring is greater consistency between operators,” added Kadir.

Mirada Medical (booth #2733) and GE Healthcare (booth #2242) will be demonstrating automatic atlas-based contouring at the annual American Society for Radiation Oncology meeting being held this year at the Georgia World Congress Center in Atlanta, Georgia, September 22-25.

For more information, please contact:

Mirada Medical

US/Worldwide: Robert Ripley                         

tel: (440) 591-8638

Insource Communications

rripley(at)insourceinc(dot)com

enquiries(at)mirada-medical(dot)com

http://www.mirada-medical.com

U.S. Headquarters:

Mirada Medical USA, Inc.

999 18th Street

Suite 2025N

Denver, CO 89292

Tel: (303) 379-9228

World Headquarters:

Oxford Centre for Innovation

New Road, Oxford

OX1 1BY

United Kingdom

Tel: +44(0)1865 261410

About Mirada Medical Ltd

Mirada Medical is a leading international brand in medical imaging. The company develops advanced software applications which help healthcare professionals use medical images more effectively and efficiently to improve cancer care. Mirada’s products are used across diagnostic radiology, molecular imaging, radiation oncology, medical oncology, tumor board and elsewhere.

The company specializes in simplifying technically complex image processing tasks, allowing clinicians to more confidently diagnose disease, assess response to treatment and plan radiation therapy or surgical intervention. Mirada’s advanced software products are available throughout the world under its own brand, and on an OEM basis through a select number of the world’s leading healthcare companies.

Mirada Medical was originally spun out of the University of Oxford. The company’s technologies and products continue to be developed by their team of specialists, engineers and world-renowned scientists at Mirada’s world headquarters in Oxford, England.

Mirada Medical, RTx, Casemeeting, Caseaccess and XD3 are all trademarks of Mirada Medical Ltd.

For the original version on PRWeb visit: http://www.prweb.com/releases/2013/9/prweb11135826.htm


Source: prweb



comments powered by Disqus